Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04305756 · ClinicalTrials.gov registry record · NA
Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery
A NA study of Thrombosis and Thromboembolism, sponsored by University of Utah.
- Completed
- Registry status
- NA
- Development phase
- 146
- Enrollment target
- 1
- Study location
NCT04305756: Completed NA study of Thrombosis and Thromboembolism, sponsored by University of Utah.
NCT04305756 is a NA study of Thrombosis and Thromboembolism that has completed, run by University of Utah. The registered enrollment target is 146 participants, below the 465-participant average among 28 other Thrombosis trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04305756, a NA study of Thrombosis and Thromboembolism, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- NA
- Development phase
- 146 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to evaluate the efficacy of two dosing regimens of low molecular weight heparin (LMWH) to reach prophylactic anti-factor Xa levels in post-cesarean delivery women. Half of participants will receive a fixed dose of LMWH, while the other half will receive a weight-based dose. The hypothesis is that the use of a weight-based dose will result in more women reaching prophylactic levels.
Primary Outcome
Anti-Xa level in prophylactic range (0.2 to 0.6 IU/mL)
Conditions Studied
Interventions
- DRUG Enoxaparin
Study Locations (1)
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2020-06-12 |
| Est. Completion | 2021-12-15 |
| Phase | NA |
What the finished NCT04305756 record still lists
NCT04305756 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 465-participant average among 28 other Thrombosis trials with a reported enrollment target (69% lower).
The record links to 3 conditions, with Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Enoxaparin is the first listed.
NCT04305756 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT04305756 about?
NCT04305756 is a clinical study titled "Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery". The aim of this study is to evaluate the efficacy of two dosing regimens of low molecular weight heparin (LMWH) to reach prophylactic anti-factor Xa levels in post-cesarean delivery women. Half of participants will receive a fixed dose of LMWH, while the other half will receive a weight-based dose. ...
What is the current status of trial NCT04305756?
This trial is currently completed. It is a NA study. The enrollment target is 146 participants. The study started on 2020-06-12. Estimated completion is 2021-12-15.
What conditions does trial NCT04305756 study?
This clinical trial studies the following conditions: Thrombosis, Thromboembolism, Postpartum DVT.
What interventions are being tested in trial NCT04305756?
The interventions under investigation include: Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT04305756?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04305756 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04305756's enrollment target sits among peer trials
146 12th of 28 higher than 17 of 28 other Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neonatal Platelet Transfusion Threshold Trial
RECRUITING · NA
-
PFA-100 Responsive to Effect of Energy Drinks on Platelet Function
COMPLETED · NA
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
-
Vascular Lab Resource (VLR) Biorepository
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI